Sleep medicine physician here. SURMOUNT-OSA is one of the most impactful obesity-related trials published in recent years, and I say that as someone who prescribes CPAP for a living.
Important clinical nuances:
- The AHI reductions are massive. A 25-point AHI reduction is the difference between severe OSA and normal. For context, CPAP typically reduces AHI to <5 when used properly, but adherence is terrible (~50% stop using it within a year). A medication-based approach that achieves this for 42% of patients is clinically transformative.
- This isn't just about the weight loss. The AHI improvements exceeded what would be predicted from weight loss alone, suggesting tirzepatide may have direct effects on upper airway physiology — possibly through reduction of pharyngeal fat deposition and/or anti-inflammatory effects on upper airway tissues.
- Quality of life metrics were also significantly improved — Epworth Sleepiness Scale, FOSQ (Functional Outcomes of Sleep Questionnaire), and patient-reported snoring all improved dramatically.
- Caveat: If you're on CPAP, do NOT stop it without a repeat sleep study and discussion with your sleep doc. Even if you feel better, untreated residual OSA can still increase cardiovascular risk.
I'm now having conversations with patients about tirzepatide as a potential CPAP exit strategy, which is something I never thought I'd say.
— Board-certified in sleep medicine and pulmonology